AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04901117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: Use according to the drug combination options selected by each center.
Study NCT04901117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Use according to the drug combination options selected by each center.
Study NCT04901117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Use according to the drug combination options selected by each center.
Study NCT04901117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Use according to the drug combination options selected by each center.
Study NCT04901117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Use according to the drug combination options selected by each center.
Study NCT04901117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Use according to the drug combination options selected by each center.
Study NCT04901117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Pectin
Description: Use according to the drug combination options selected by each center.
Study NCT04901117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal Bismuth Pectin
Description: Use according to the drug combination options selected by each center.
Study NCT04935931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: naltrexone 50 mg PO x 1
Study NCT04901117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan fumarate
Description: Use according to the drug combination options selected by each center.
Study NCT04901117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan fumarate
Description: Use according to the drug combination options selected by each center.
Study NCT05613634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: A high frequency (10 Hz) rTMs on the dominant dorsolateral prefrontal cortex (DLPFC) was applied with the Magstim Rapid Magnetic Stimulator, Magstim Company. Patients were seated in a chair, arms and legs relaxed, head stable, and no movement was allowed during the procedure. Motor threshold (MT) was determined before each session and was defined as the percent intensity output of the stimulator that generated a 50µV motor evoked response in the abductor pollicis brevis (APB) muscle in five out of 10 trials. The DLPFC of dominant hemisphere was localized on the scalp 5.5 cm anterior to the hot spot for the contralateral APB muscle along the parasagittal plane. The average MT was 50 % (range, 45-55%) of the maximal output of the stimulator. The initial mapping procedure was completed with the coil oriented at 45° lateral diagonal orientation roughly perpendicular to the central sulcus and the center of the coil applied tangentially to the scalp.
Study NCT05613634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cawthorne Cooksey exercises
Description: Cawthorne Cooksey exercises were carried in the following sequence: First, bed exercises; eye movements (up and down, side to side, focusing on a finger that is one feet distance); head movements (bending up and down, side to side first with eye opened then closed). Second, sitting exercises involved same eye and head movements, shoulder shrugging, turning head and trunk alternately to the right and left, bending head and trunk forward, and pick an object from the ground. Third, standing exercises involved same eye, head, and shoulder movements, changing position from sitting to standing with eye open then closed, throw a ball from hand to hand above eye level, throw a ball from hand to hand beneath knee, changing position from sitting to standing and turn around in between. Fourth, moving around exercises where the patient revolved around a person sitting in the center who throw him a ball and to whom it was returned.
Study NCT05310825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Wiping Bath with Single-Use Wipes
Description: Cleaning wipes will be used in the bathing process which do not contain alcohol, paraben or latex. These wipes are a product routinely used in patient hygiene procedures in the intensive care unit where the study is to be conducted. Before taking them out of the packet, the wipes to be used in the bathing will be heated according to usage instructions at 850W for 50 seconds in a microwave oven which will be brought by the researcher The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated.
Study NCT05310825 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Body Wiping Bath
Description: The rubbing cloth to be used with both the soapy and the rinsing water in the routine procedure will have an inner layer of pure cotton with an outer layer of hydrophilic gauze. The patient's body wash will be performed with this cloth, using foam from the soapy water. As soon as the bathing procedure is commenced, a chronometer will be started by another nurse who is independent of the study.~The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated
Study NCT06391827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-7503 Single dose
Description: Oral administration for once; Dose strength is different for each cohort(Cohort 1, 2, 3, 4 and 5).
Study NCT06391827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-7503 Multiple dose
Description: Oral administration once daily for 7 days; Dose strength or target volunteer is different for each cohort(Cohort 1,2,3, and 4)
Study NCT06391827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Single dose
Description: Oral administraion for once.
Study NCT06391827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Multiple dose
Description: Oral administration once daily for 7 days
Study NCT05673694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG017
Description: According to the dosage group of the program, once a day.
Study NCT05356559 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: 12.5g (twice daily) Blue Whiting Protein Hydrolysates daily for 8 weeks
Study NCT06393673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10384 tablet Dose 1
Description: Administered orally QD
Study NCT06393673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10384 tablet Dose 2
Description: Administered orally QD
Study NCT06393673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10384-matched placebo tablets
Description: Administered orally QD
Study NCT06393673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-10384-matched placebo tablets
Description: Administered orally QD
Study NCT05672394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Serratus anterior plane block
Description: in lateral position a linear transducer (10-12MHz, M-Turbo) will be used, The 5th rib is identified in the mid-axillary line. The following muscles are overlying the rib latissimusdorsi ,teres major, and serratus muscle.The needle (22G, 50-mm Tuohy needle) is introduced in-plane targeting the plane superficial to serratus muscle. local anesthetic is injected then a catheter is threaded and . Ultrasound-guided SAPB was done using a serratus anterior catheter Group DL (n=20) received a bolus of 30 mL of 0.25% bupivacaine followed by a continuous infusion of 0.125% bupivacaine at a rate of 7-12 ml/hr according to patient response upon ICU arrival after the stabilization of the clinical status. The infusion was continued until the end of the 1st 24 hours postoperatively .
Study NCT05672394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural
Description: A thoracic epidural catheter was done to the patient while sitting. Tuohy needles are used. Epidural space can be identified by loss of resistance. Injection begins with a negative aspiration and a test dose (3 ccs of 1.5% lidocaine with 1:200,000 epinephrine) .A Continuous epidural technique through the placement of a catheter 3-5 cm beyond the needle is applied. Injection in 5ml increments of 0.25% bupivacaine is used until the block of the required segments achieved ( 10 to 15ml). sensory testing is via pinprick and cold test to detect sympathetic block . Throughout the technique hourly injection of 5 ml 0.25% bupivacaine for maintenance.
Study NCT05672394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: bupivacaine
Study NCT05672394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine
Study NCT05672394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine with epinephrine
Description: 3 ccs of 1.5% lidocaine with 1:200,000 epinephrine
Study NCT04790903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants will receive Doxorubicin at a dose of 50 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
Study NCT05356559 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Isocalorific Maltodextrin Citrus Flavoured Powder for 8 weeks
Study NCT04790903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive Prednisone orally (PO) at a dose of 100 mg/day on Days 1-5 of Cycles 1-6.
Study NCT04784091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-03
Description: TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
Study NCT04784091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TP-03 Vehicle
Description: Vehicle of TP-03 ophthalmic solution, administered twice a day
Study NCT05306106 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose
Description: Each subject will consume the reference product during visits V1 and V5. A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume the glucose solution. The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes.
Study NCT05306106 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: truffle match
Description: The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 221.2 g of truffle match (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes.
Study NCT05306106 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hazelnut chocolate cookie
Description: The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 142.8 g of hazelnut chocolate cookie (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes.
Study NCT05306106 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Paris Brest style eclair
Description: The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 277.7 g of Paris Brest style eclair (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes.
Study NCT05306106 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hazelnut chocolate finger
Description: The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 312.5 g of hazelnut chocolate finger (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes.
Study NCT05306106 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: lemon finger
Description: The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 263.1 g of lemon finger (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes.
Study NCT05736432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberries
Description: Experimental condition
Study NCT05736432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo condition
Study NCT06109402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: Specified dose on specified days
Study NCT06109402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT06109402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days
Study NCT06109402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Specified dose on specified days
Study NCT06109402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery for II-IIIB (N2) non-small cell lung cancer
Study NCT06537609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: De-escalation VS No De-escalation
Description: No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result). De-escalation is only allowed within 7 days if patient is being discharged from hospital.~De-escalation group: switched to narrower spectrum antibiotic (based on spectrum scale specified in protocol).
Study NCT06537609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral beta-lactams VS non beta-lactams
Description: Beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime.~Non beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole.
Study NCT06537609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Central vascular catheter retention VS Central vascular catheter replacement
Description: Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization~Central vascular catheter retention: the catheter will not be changed and will be retained until it is non functional or no longer needed.
Study NCT06537609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cephalosporin VS Carbapenem for low risk AmpC organisms
Description: Cephalosporin (ceftriaxone) at standard doses~Carbapenem (Meropenem or Ertapenem) at standard doses
Study NCT06537609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine follow-up blood culture VS No routine follow-up blood culture
Description: Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.~No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria
Study NCT05791097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Ociperlimab is a monoclonal antibody formulated for intravenous infusion. 900 mg of ociperlimab will be administered on Day 1 of each 21-day cycle
Study NCT05791097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo infusions will consist of a sterile, normal saline solution. Placebo will be administered on Day 1 of each 21-day cycle
Study NCT05306106 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: elderflower madeleine
Description: The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 294.1 g of elderflower madeleine (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes.
Study NCT06571461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: Liposomal Irinotecan：i.v. infusion
Study NCT06571461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin;：i.v. infusion
Study NCT06571461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1: Oral
Study NCT06571461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine: i.v. infusion
Study NCT06571461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine: Oral
Study NCT04840745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-841 A-1 3.75mg
Description: Single injection, subcutaneous injection
Study NCT04840745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-841 A-1 1.88mg
Description: Single injection, subcutaneous injection
Study NCT04840745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-841 D 2.92mg
Description: Single injection, subcutaneous injection
Study NCT04840745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuplin Inj. 3.75 mg
Description: Single injection, subcutaneous injection
Study NCT04928352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Preoperative Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
Study NCT04928352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Preoperative Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
Study NCT04928352 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Preoperative nebulized same volume of saline placebo